4568
DAIICHI SANKYO COMPANY,LIMITED
第一三共
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
1,044,892
Mar 2023
1,278,478
Mar 2024
1,601,688
Mar 2025
1,886,256
Mar 2026
2,123,045
Operating profit(million JPY)
Mar 2022
73,025
Mar 2023
120,580
Mar 2024
211,588
Mar 2025
331,925
Mar 2026
229,089
Operating profit margin(%)
Mar 2022
6.99
Mar 2023
9.43
Mar 2024
13.21
Mar 2025
17.6
Mar 2026
10.79
Profit before tax(million JPY)
Mar 2022
73,516
Mar 2023
126,854
Mar 2024
237,234
Mar 2025
355,631
Mar 2026
263,432
Profit(million JPY)
Mar 2022
66,972
Mar 2023
109,188
Mar 2024
200,731
Mar 2025
295,756
Mar 2026
259,874
Total assets(million JPY)
Mar 2022
2,221,402
Mar 2023
2,508,889
Mar 2024
3,461,135
Mar 2025
3,456,119
Mar 2026
4,005,390
Cash and cash equivalents(million JPY)
Mar 2022
662,477
Mar 2023
441,921
Mar 2024
647,180
Mar 2025
639,838
Mar 2026
449,807
Cash flows from operating activities(million JPY)
Mar 2022
139,226
Mar 2023
114,514
Mar 2024
599,258
Mar 2025
53,842
Mar 2026
77,655
Cash flows from investing activities(million JPY)
Mar 2022
212,339
Mar 2023
-257,782
Mar 2024
-282,636
Mar 2025
334,170
Mar 2026
-148,241
Cash flows from financing activities(million JPY)
Mar 2022
-86,231
Mar 2023
-89,594
Mar 2024
-123,564
Mar 2025
-377,769
Mar 2026
-97,875
Return on equity(%)
Mar 2022
5.1
Mar 2023
7.8
Mar 2024
12.8
Mar 2025
17.9
Mar 2026
15.8
Equity ratio(%)
Mar 2022
60.8
Mar 2023
57.6
Mar 2024
48.8
Mar 2025
47
Mar 2026
41.5
Earnings per share(JPY per share)
Mar 2022
34.94
Mar 2023
56.96
Mar 2024
104.69
Mar 2025
155.96
Mar 2026
140.44
Net assets per share(JPY per share)
Mar 2022
704.76
Mar 2023
754.09
Mar 2024
880.4
Mar 2025
869.69
Mar 2026
914.56
Dividend per share(JPY per share)
Mar 2022
27
Mar 2023
30
Mar 2024
50
Mar 2025
60
Mar 2026
78
Payout ratio(%)
Mar 2022
77.28
Mar 2023
52.67
Mar 2024
47.76
Mar 2025
38.47
Mar 2026
55.54
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.